Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on by Top Pharmaceutical

Excellence in Research Award


Aniela Montserrat Silva Nolasco

Universidad de Castilla-La Mancha, Spain


Aniela Montserrat Silva Nolasco
Affiliation Universidad de Castilla-La Mancha
Country Spain
Scopus ID
57221107566
Documents 21
Citations 23
h-index 2
Subject Area Pharmaceutical Chemistry
Event International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
  2. ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
  3. Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
  4. Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
  5. Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294

Liangqun Li | Pharmaceutical Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Liangqun Li | Pharmaceutical Chemistry | Best Researcher Award

Natural Products Research Center of Guizhou Province | China

Dr. Liangqun Li is a distinguished researcher in natural products chemistry, medicinal chemistry, and functional natural product development, widely recognized for his contributions to the scientific understanding of bioactive plant compounds, particularly those derived from Guizhou’s characteristic botanical resources such as Rosa roxburghii. As a Researcher at the Guizhou Research Center for Natural Products, the National Key Laboratory of Efficacy Components of Traditional Chinese Medicine and Their Utilization, and the Institute of Functional Natural Products, he leads high-impact investigations into efficacy material basis, molecular pathways, and translational utilization of natural compounds. Dr. Li’s scholarly influence is reflected in his strong research metrics, with 293 citations from 275 citing documents, 35 published documents, and an h-index of 11, underscoring his growing global impact in the fields of natural products, phytochemistry, and medicinal biosciences. Before his current role, he completed a productive postdoctoral fellowship at the Key Laboratory of Plant Resources & Biotechnology, Kunming Institute of Botany, Chinese Academy of Sciences, advancing the identification and functional analysis of key genes involved in pennogenin saponin biosynthesis in Paris polyphylla var. yunnanensis. His earlier experience as an R&D Specialist at Yunnan Baiyao Group strengthened his expertise in pharmaceutical formulation, chemical generic drug development, innovative health-care products, and applied medicinal chemistry. Dr. Li earned his Doctor of Science in Medicinal Chemistry from the Kunming Institute of Botany in collaboration with Yunnan University, preceded by a Master of Pharmacy and a Bachelor of Pharmacy from Kunming Medical University and Haiyuan College. His scholarly contributions include significant publications such as Effects and formula optimization of Rosa roxburghii pomace substrate on the yield and volatile flavor compounds of Lentinula edodes, Therapeutic potential of Rosa roxburghii folium extract in insomnia treatment, Combined metabolite and transcriptomic profiling unveil a potential gene network involved in the triterpenoid metabolism of Rosa roxburghii, Acer truncatum seed oil and Rosa roxburghii juice submicron emulsion: preparation and its therapeutic potential in alleviating scopolamine-induced memory impairment in mice, Isolation, identification, phytochemical characterization and in vitro anti-inflammatory property of an endophytic Trametes versicolor CL-1 isolated from Rosa roxburghii, In vitro neurotrophic properties and structural characterization of a new polysaccharide LTC-1 from Pyrola corbieri Levl, Effect on hypoglycemic activity and UPLC-MS/MS profiling of Rosa roxburghii fruit fermented with Chinese traditional distiller’s yeast, Preparation and characterization of calcium-incorporated Rosa roxburghii Tratt and its efficacy on bone mineral density in rats, Microbial transformation of diosgenin to diosgenone by Wickerhamomyces anomalus JQ-1, and multiple works on asymmetric total synthesis of natural product derivatives including triptophenolide, triptolide, dichroanone, taiwaniaquinone H, brazilin, brazilein, and brazilide A. Through his integrated research combining metabolomics, transcriptomics, biosynthesis, phytochemistry, and innovative natural product engineering, Dr. Li continues to advance the scientific landscape of medicinal plants, contributing to novel therapeutic insights, biochemical pathway discovery, and the modernization of traditional medicinal resources.

Profile: Scopus

Featured Publications

Authors. (2025). Targeted discovery of oxygen-bridged sesquiterpenes from Cinnamomum migao by MS/MS-based molecular networking and their neuroprotective activities. Phytochemistry.

Authors. (2025). Iridoid constituents and anti-aging activity of Eucommiae Folium. Shipin Kexue Food Science.

Authors. (2025). Therapeutic potential of Rosa roxburghii folium extract in insomnia treatment: A comprehensive evaluation of behavioral and neurochemical effects in a PCPA-induced mouse model. Journal of the Science of Food and Agriculture.